Page 1073 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

28. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count- 45. French MA, Price P, Stone SF. Immune restoration disease after
guided interruption of antiretroviral treatment. N Engl J Med. antiretroviral therapy. AIDS. 2004;18:1615-1627.
2006;355:2283-2296. 46. Cheng VC, Yuen KY, Chan WM, Wong SS, Ma ES, Chan RM.
29. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagula- Immunorestitution disease involving the innate and adaptive
tion biomarkers and mortality in patients with HIV infection. response. Clin Infect Dis. 2000;30:882-892.
PLoS Med. 2008;5:e203. 47. Murdoch DM, Venter WD, Van Rie A, Feldman C. Immune
30. Williams I, Churchill D, Anderson J, et al. BHIVA Guidelines reconstitution inflammatory syndrome (IRIS): review of com-
for the treatment of HIV-1 positive adults with antiretroviral mon infectious manifestations and treatment options. AIDS Res
therapy 2012. Ther. 2007;4:9.
31. Scott JD. Simplifying the treatment of HIV infection with rito- 48. Robertson J, Meier M, Wall J, Ying J, Fichtenbaum CJ. Immune
navir-boosted protease inhibitors in antiretroviral-experienced reconstitution syndrome in HIV: validating a case definition
patients. Am J Health Syst Pharm. 2005;62:809-815. and identifying clinical predictors in persons initiating antiret-
32. Youle M. Overview of boosted protease inhibitors in treatment- roviral therapy. Clin Infect Dis. 2006;42:1639-1646.
experienced HIV-infected patients. J Antimicrob Chemother. 49. Phillips P, Bonner S, Gataric N, et al. Nontuberculous myco-
2007;60:1195-1205. bacterial immune reconstitution syndrome in HIV-infected
33. Hull MW, Montaner JS. Ritonavir-boosted protease inhibitors patients: spectrum of disease and long-term follow-up. Clin
in HIV therapy. Ann Med. 2011;43:375-388. Infect Dis. 2005;41:1483-1497.
34. Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat 50. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococ-
versus ritonavir as a pharmacoenhancer for atazanavir plus cosis after initiation of successful highly active antiretroviral
emtricitabine/tenofovir DF in treatment-naive HIV-1-infected therapy. Clin Infect Dis. 2002;35:e128-e133.
patients: Week 48 results. J Infect Dis. 2013. 51. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical
35. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvite- worsening of tuberculosis following antiretroviral ther-
gravir, cobicistat, emtricitabine, and tenofovir disoproxil fuma- apy in patients with AIDS. Am J Respir Crit Care Med.
rate versus ritonavir-boosted atazanavir plus co-formulated 1998;158:157-161.
emtricitabine and tenofovir disoproxil fumarate for initial treat- 52. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated
ment of HIV-1 infection: a randomised, double-blind, phase 3, immune reconstitution inflammatory syndrome: case defini-
non-inferiority trial. Lancet. 2012;379:2429-2438. tions for use in resource-limited settings. Lancet Infect Dis.
36. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral 2008;8:516-523.
therapy reduces AIDS progression/death in individuals with 53. Dean GL, Williams DI, Churchill DR, Fisher MJ. Transient
acute opportunistic infections: a multicenter randomized strat- clinical deterioration in HIV patients with Pneumocystis carinii
egy trial. PLoS One. 2009;4:e5575. pneumonia after starting highly active antiretroviral therapy:
37. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of another case of immune restoration inflammatory syndrome.
HIV-associated tuberculosis in the era of highly active antiret- Am J Respir Crit Care Med. 2002;165:1670.
roviral therapy. J Infect Dis. 2004;190:1670-1676. 54. Barry SM, Lipman MC, Deery AR, Johnson MA, Janossy G.
38. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initia- Immune reconstitution pneumonitis following Pneumocystis
tion of antiretroviral drugs during tuberculosis therapy. N Engl carinii pneumonia in HIV-infected subjects. HIV Med.
J Med. 2010;362:697-706. 2002;3:207-211.
39. Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral 55. Wislez M, Bergot E, Antoine M, et al. Acute respiratory fail-
therapy for HIV-1 infection and tuberculosis. N Engl J Med. ure following HAART introduction in patients treated for
2011;365:1482-1491. Pneumocystis carinii pneumonia. Am J Respir Crit Care Med.
40. Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of 2001;164:847-851.
antiretroviral therapy in HIV-infected adults with tuberculosis. 56. Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitu-
N Engl J Med. 2011;365:1471-1481. tion inflammatory syndrome in HIV-associated cryptococcal
41. Fox Z, Phillips A, Cohen C, et al. Viral resuppression and detec- meningitis: a prospective study. J Acquir Immune Defic Syndr.
tion of drug resistance following interruption of a suppressive 2009;51:130-134.
non-nucleoside reverse transcriptase inhibitor-based regimen. 57. Makadzange AT, Ndhlovu CE, Takarinda K, et al. Early versus
AIDS. 2008;22:2279-2289. delayed initiation of antiretroviral therapy for concurrent HIV
42. Taylor S, Boffito M, Khoo S, Smit E, Back D. Stopping antiretro- infection and cryptococcal meningitis in sub-saharan Africa.
viral therapy. AIDS. 2007;21:1673-1682. Clin Infect Dis. 2010;50:1532-1538.
43. Chen F, Kearney T, Robinson S, Daley-Yates PT, Waldron S, 58. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized
Churchill DR. Cushing’s syndrome and severe adrenal suppres- placebo-controlled trial of prednisone for paradoxical
sion in patients treated with ritonavir and inhaled nasal flutica- tuberculosis-associated immune reconstitution inflammatory
sone. Sex Transm Infect. 1999;75:274. syndrome. AIDS. 2010;24:2381-2390.
44. Clevenbergh P, Corcostegui M, Gerard D, et al. Iatrogenic 59. Huang L, Quartin A, Jones D, Havlir DV. Intensive care of
Cushing’s syndrome in an HIV-infected patient treated with patients with HIV infection. N Engl J Med. 2006;355:173-181.
inhaled corticosteroids (fluticasone propionate) and low 60. Akgun KM, Pisani M, Crothers K. The changing epidemiology
dose ritonavir enhanced PI containing regimen. J Infect. of HIV-infected patients in the intensive care unit. J Intensive
2002;44:194-195. Care Med. 2011;26:151-164.

Section05-O-ref.indd 2 1/20/2015 4:51:21 PM